Politics / Law

EU to review biofuel sustainability

13.06.2011

Brussels – Until now, deforestation due to the planting of biofuel crops hasn’t been taken into account when calculating eco-balances for biofuel production. However, it could be the source of vast quantities of greenhouse gases, especially when farmers sell land to bio­fuel producers and then burn forests to clear more for food production. By July, the European Commission will publish a report addressing the question, and it’s already dividing the biofuel industry. Looking at 15 bio­fuel crops, the paper will for the first time analyse the impact of so-called indirect land use change (ILUC) on the sustainability of biofuels – which currently have annual markets totalling EUR11.4bn.
For most companies relying on first-generation biofuels made from corn or wheat starch, the Commission’s review of its bio­fuel strategy is bad news. If ILUC in fact worsens the eco-balance of their products, it would directly contradict the EU’s sustainability goals, thus limiting sales. In a European Parliament environment panel debate about the Commission’s plans, Austrian MEP Karin Kadenbach said that “it is not acceptable that biofuels are produced at the cost of food production, especially as long as it has not been proven that they offer benefits for the climate.”
But for companies like Novozymes or Süd-Chemie (now part of Clariant), which have developed technologies to make bioethanol from straw (see EuroBiotechNews 7-8/2010), the Commission’s plan could open up new market opportunities. Their second-generation bio­fuels are ILUC-

neutral. “ILUC could create a window of opportunities,” says Novozymes’ Kare Nielsen. He predicts straw-based biofuels could become competitive with petroleum products by 2020. In June, the International Energy Agency reported that climate-warming emissions rose by 5% in 2010.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/eu-to-review-biofuel-sustainability.html

Events

All Events

Stock list

All quotes

TOP

  • SUMMIT (UK)4.03 GBP3.87%
  • ZELTIA (E)2.89 EUR3.58%
  • 4SC (D)1.30 EUR0.00%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)6.36 EUR-12.40%

TOP

  • WILEX (D)2.70 EUR221.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK49.8%
  • Allergy Therapeutics (UK)20.00 GBP33.3%

FLOP

  • HYBRIGENICS (F)1.57 EUR-33.2%
  • STENTYS (F)6.36 EUR-30.0%
  • PROTHENA PLC (IE)17.36 USD-23.2%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR290.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.0%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.07 EUR-71.3%

No liability assumed, Date: 01.08.2014


Current issue

All issues

Product of the week

Products